AMYT.L Share News (AMYT)

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is

Amryt 2017 Revenue Soars On Lojuxta Sales As New In-Licence Sealed

LONDON (Alliance News) - Amryt Pharma PLC said Thursday it has signed an in-licence agreement for a gene therapy platform, with the company making a "very start in for to

UK Stocks-Factors to watch on March 15

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2 points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 9 March SIGFull Year ResultsInmarsatFull Year ResultsGVC Year 12

Amryt Pharma Gets Positive Study Results For Possible Acromegaly Drug

Amryt Pharma secures €20m loan from European Investment Bank

(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi

Amryt Pharma's drug compound gains FDA approval

(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg

Amryt Pharma positive about drug developments

(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

Amryt Pharma reverses onto AIM to advance orphan drug strategy

(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com

Amryt Pharma Starts Trading After Fastnet Reverse Takeover (ALLIPO)